DNase I variants, compositions, methods, and kits
The present disclosure relates, according to some embodiments, to systems, apparatus, compositions, methods, and workflows that include DNase I variants with desirable properties including, for example, salt tolerance. A DNase I variant, in some embodiments, may have an amino acid sequence that is at least 85% identical, at least 90% identical, at least 95% identical, and/or at least 98% identical to SEQ ID NO:1 and may be identical to SEQ ID NO:1 at one or more positions selected from the group of positions corresponding to L29, A35, D87, Q88, S94, P103, T108, P121, P132, A135, D145, E161, G172, P190, H208, and A224 of SEQ ID NO:1.
1. A DNase I variant having an amino acid sequence that is (a) at least 95% identical to SEQ ID NO:1 and (b) identical to SEQ ID NO:1 at one or more positions corresponding to L29, A35, D87, Q88, S94, P103, T108, P121, P132, A135, D145, E161, G172, P190, H208, and A224 of the polypeptide of SEQ ID NO:1, wherein said variant has DNase I activity.
2. The DNase I variant according to claim 1 , wherein the amino acid sequence is identical to SEQ ID NO: 1 at one or more positions corresponding to E13, N18, S43, H44, N74, S75, P103, N106, T205, S206, and T207 of the polypeptide of SEQ ID NO: 1.
3. The DNase I variant according to claim 1 , wherein the amino acid sequence comprises one or more substitutions at positions corresponding to SEQ ID NO:1, wherein the substitutions and corresponding positions are selected from A22S, R305, V46T, and V163I of the polypeptide of SEQ ID NO:1.
4. The DNase I variant according to claim 1 , wherein the amino acid sequence comprises one or more substitutions at positions corresponding to SEQ ID NO:1, wherein the substitutions and corresponding positions are selected from E13K, E13R, N18A, A35V, S43K, S43R, H44K, H44R, N74K, N74R, S75K, S75R, P103S, N106A, T205K, T205R, S206K, S206R, T207K, and T207R of the polypeptide of SEQ ID NO:1.
5. The DNase I variant according to claim 1 , wherein the amino acid sequence comprises two or more substitutions at positions corresponding to SEQ ID NO:1, wherein the substitutions and corresponding positions are selected from E13K, E13R, N18A, A35V, S43K, S43R, H44K, H44R, N74K, N74R, S75K, S75R, P103S, N106A, T205K, T205R, S206K, S206R, T207K, and T207R of the polypeptide of SEQ ID NO:1.
6. The DNase I variant according to claim 1 , wherein the amino acid sequence comprises three or more substitutions at positions corresponding to SEQ ID NO:1, the substitutions and corresponding positions selected from E13K, E13R, N18A, A35V, S43K, S43R, H44K, H44R, N74K, N74R, S75K, S75R, P103S, N106A, T205K, T205R, S206K, S206R, T207K, and T207R of the polypeptide of SEQ ID NO: 1.
7. A DNase I variant having an amino acid sequence (I) that is at least 95% identical to SEQ ID NO:1 and (II) that comprises one or more of:
(a) a lysine or arginine at a position corresponding to position 13 of the polypeptide of SEQ ID NO:1,
(b) a lysine or arginine at a position corresponding to position 43 of the polypeptide of SEQ ID NO:1,
(c) a lysine or arginine at a position corresponding to position 44 of the polypeptide of SEQ ID NO:1,
(d) a lysine or arginine at a position corresponding to position 74 of the polypeptide of SEQ ID NO:1,
(e) a lysine or arginine at a position corresponding to position 75 of the polypeptide of SEQ ID NO:1,
(f) a lysine or arginine at a position corresponding to position 205 of the polypeptide of SEQ ID NO:1,
(g) a lysine or arginine at a position corresponding to position 206 of the polypeptide of SEQ ID NO:1,
(h) a lysine or arginine at a position corresponding to position 207 of the polypeptide of SEQ ID NO:1; and
wherein said variant has DNase I activity.
8. The DNase I variant according to claim 7 , wherein the amino acid sequence comprises two or more of:
(a) a lysine or arginine at a position corresponding to position 13 of the polypeptide of SEQ ID NO:1,
(b) a lysine or arginine at a position corresponding to position 43 of the polypeptide of SEQ ID NO:1,
(c) a lysine or arginine at a position corresponding to position 44 of the polypeptide of SEQ ID NO:1,
(d) a lysine or arginine at a position corresponding to position 74 of the polypeptide of SEQ ID NO:1,
(e) a lysine or arginine at a position corresponding to position 75 of the polypeptide of SEQ ID NO:1,
(f) a lysine or arginine at a position corresponding to position 205 of the polypeptide of SEQ ID NO:1,
(g) a lysine or arginine at a position corresponding to position 206 of the polypeptide of SEQ ID NO:1, and
(h) a lysine or arginine at a position corresponding to position 207 of the polypeptide of SEQ ID NO:1.
9. The DNase I variant according to claim 7 , wherein the amino acid sequence comprises one or more of:
(a) a valine at a position corresponding to position 35 of SEQ ID NO:1, and
(b) a serine at a position corresponding to position 103 of SEQ ID NO:1.
10. A DNase I variant having an amino acid sequence that is at least 98% identical to SEQ ID NO:1, wherein said variant has DNase I activity.
11. The DNase I variant according to claim 10 , wherein the amino acid sequence is not identical to SEQ ID NO:1 at one or more positions corresponding to E13, N18, A35, S43, H44, N74, S75, P103, N106, T205, S206, and T207 of the polypeptide of SEQ ID NO:1.
12. A DNase I variant comprising an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 1, 5, 7, 8, or 9.
13. The DNase I variant according claim 1 , wherein the DNase I variant has at least 30% of its peak catalytic activity in the presence of a total salt concentration of 0 mM to 300 mM.
14. A DNase I variant having an amino acid sequence having at least 93% identity to SEQ ID NO:3 and comprising one or more substitutions at positions corresponding to SEQ ID NO:3, the substitutions and corresponding positions selected from N18A, S43K, S43R, S103X, N106A, S206K, S206R, T207K, and T207R, wherein said variant has DNase I activity.
15. A fusion protein comprising a single polypeptide chain, the single peptide chain comprising:
(a) the DNase I variant according to claim 1 ; and
(b) at least one of an affinity tag, a secretion signal, and a linker.
16. A method for hydrolyzing DNA comprising contacting (a) a composition comprising DNA and optionally RNA, and (b) the DNase I variant according to claim 1 to form a reaction mixture comprising DNA hydrolysis products.
17. The method according to claim 16 , wherein the reaction mixture has a total salt concentration of 0 mM to 300 mM.
18. The method according to claim 16 , wherein the composition comprises RNA and the reaction mixture comprises at least 90% of the RNA that was in the composition.
19. The method according to claim 16 , wherein the reaction mixture comprises less than 10% of the DNA that was in the composition.
20. The method according to claim 16 , wherein the reaction mixture further comprises a DNase I buffer or a high magnesium buffer.
21. A composition comprising the DNase I variant according to claim 1 and one or more salts at a total salt concentration of at least 50 mM.
22. The composition according to claim 21 further comprising one or more enzymes other than the DNase I variant.
23. A composition comprising the DNase I variant according to claim 1 , wherein the composition has a form selected from a gel, a film, a powder, a cake, a dried form, and a lyophilized form.
24. A composition comprising the DNase I variant according to claim 1 and one or more of a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, starch, cellulose, dextrin, and dextran.